Vaccine Cell Substrates 2004
June 29 - July 1, 2004
Rockville, MD
Viral vaccine development is tied closely with cell substrate choice and the limitations that the currently acceptable cell substrates impose on vaccine development. Many scientific issues have hampered significant progress in widening the available choices of cell substrates for vaccine production, particularly continuous cell lines. The purpose of Vaccine Cell Substrates 2004 meeting was to inform the field of existing data on progress in addressing specific scientific issues identified below, to discuss the continued validity of existing tests and appropriateness of new ones, and to develop consensus recommendations for the field to address these issues, either by implementing suggested recommendations or identifying research gaps that preclude decision-making.
The specific scientific issues covered included the following topic areas:
- Oncogenicity of cellular components, including latent viruses and cellular DNA
- In vivo viral adventitious agent test methods
- Level of assurance provided by current tests
- Bovine (and porcine) viruses in bovine-derived raw materials (particularly serum)
- Bovine spongiform encephalopathy (BSE) agents as potential cell substrate contaminants
List of meeting presentations
If you would like to receive a copy of any of the presentations, please contact Rebecca Sheets at rsheets@niaid.nih.gov.
Meeting Summary:
Vaccine cell substrates 2004
Sheets R, Petricciani J.
Expert Rev Vaccines. 2004. Dec;3(6):633-8.